CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces the publication of data demonstrating the clinical utility of measuring AlloSure in repeat kidney transplant recipients in the American Journal of Transplantation.
December 21, 2018
· 2 min read